CN113621135A - Branched polyamino acid bacteriostatic agent and application thereof - Google Patents
Branched polyamino acid bacteriostatic agent and application thereof Download PDFInfo
- Publication number
- CN113621135A CN113621135A CN202111043610.6A CN202111043610A CN113621135A CN 113621135 A CN113621135 A CN 113621135A CN 202111043610 A CN202111043610 A CN 202111043610A CN 113621135 A CN113621135 A CN 113621135A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- bacteriostatic agent
- polyamino acid
- derivatives
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 title claims abstract description 67
- 239000000022 bacteriostatic agent Substances 0.000 title claims abstract description 33
- 150000001413 amino acids Chemical class 0.000 claims abstract description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 229920000642 polymer Polymers 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 229960003767 alanine Drugs 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960003121 arginine Drugs 0.000 claims description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 8
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003646 lysine Drugs 0.000 claims description 8
- 229960003104 ornithine Drugs 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229960003136 leucine Drugs 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 235000008521 threonine Nutrition 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 235000002374 tyrosine Nutrition 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract description 3
- 239000012620 biological material Substances 0.000 abstract description 2
- 125000000524 functional group Chemical group 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 238000010438 heat treatment Methods 0.000 description 23
- 239000003242 anti bacterial agent Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 230000001376 precipitating effect Effects 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 8
- 238000005086 pumping Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 5
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 229920002413 Polyhexanide Polymers 0.000 description 5
- 239000012752 auxiliary agent Substances 0.000 description 5
- 229960005337 lysine hydrochloride Drugs 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- -1 amino acid salt Chemical class 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- RBZRMBCLZMEYEH-UHFFFAOYSA-N 1h-pyrazol-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1C=CC=N1 RBZRMBCLZMEYEH-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001495 arsenic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940093920 gynecological arsenic compound Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Polyamides (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention provides a branched polyamino acid bacteriostatic agent, which comprises branched polyamino acid; the branched polyamino acid is obtained by copolymerizing two or more than two amino acid units. The raw materials used by the invention are various amino acids, are all natural biological materials, have no toxicity and no side effect, are a novel environment-friendly bacteriostatic agent, and are easy to accept by users. The branched structure of the polyamino acid enables the substance to have a plurality of active functional groups, can be further modified, has good biocompatibility, can tear a bacterial film to cause death, and cannot generate drug resistance after long-term use.
Description
The application is a divisional application with the application number of 201810096221.1, application date of 2018, 1 month and 31 days, and the invention name of branched polyamino acid bacteriostatic agent and application.
Technical Field
The invention relates to the technical field of bacteriostats, in particular to a branched polyamino acid bacteriostat and application thereof.
Background
The invention of antibiotics saves hundreds of millions of people's lives, and the people are free from the pain of bacterial infection, so the invention is a revolution in medicine. However, with the abuse of small molecule antibiotics, coupled with the short life cycle and gene level transfer characteristics of bacteria, various drug resistant bacteria have emerged. The spread of pathogenic bacteria is even more serious, endangering people's normal life. One recent study showed that by 2050 superbacteria, if not controlled, would result in approximately 1000 million people per year. Drug-resistant bacteria have become a hot spot of general concern in countries around the world, and are related to the health of human beings, the development of economy and the stability of society all over the world.
Compared with micromolecular antibiotics, the polymer bacteriostatic agent can be non-specifically combined with a negatively charged bacterial membrane and then inserted into the bacterial membrane to cause the bacterial membrane to be broken and further kill bacteria, so that the polymer bacteriostatic agent is not easy to generate drug resistance. Therefore, the development and use of the bacteriostatic polymer material which has high safety, good bacteriostatic effect, sustainable use and biodegradability is a significant topic with profound significance.
Amino acid is a renewable resource, is mainly synthesized by hydrolyzing and fermenting biomass (starch, cellulose and the like) raw materials, and the global annual yield reaches megaton level. At present, amino acid is mainly used as food and feed additives, and the additional value is low. How to develop a new high value-added product is a problem which needs to be solved urgently in the amino acid industry. The application of the branched polyamino acid in the bacteriostatic field is not reported so far.
Disclosure of Invention
In view of the above, the technical problem to be solved by the present invention is to provide a branched polyamino acid bacteriostatic agent and an application thereof, wherein the branched polyamino acid polymer prepared by using amino acid as a raw material has excellent bacteriostatic performance.
In order to solve the technical problems, the invention provides a branched polyamino acid bacteriostatic agent, which comprises branched polyamino acid;
the branched polyamino acid is obtained by copolymerizing two or more than two amino acid units;
the amino acid unit has a general structural formula shown in formula I or a salt thereof:
wherein,
a. b, c, d, e and f are independent integers of 0-6, and a + b + c + d + e + f is more than or equal to 1 and less than or equal to 20;
the T is1、T2、T3、T4、T5And T6Independently selected from any of the following knotsStructure:
and T of at least one amino acid1、T2、T3、T4、T5、T6At least one of which is
The salt may be an amino acid salt well known to those skilled in the art, preferably a hydrochloride, sulfate, phosphate, carbonate or nitrate salt.
Preferably, a + b + c + d + e + f is less than or equal to 10.
Preferably, the branched polyamino acid is obtained by copolymerizing two or more branch point amino acid units; or is copolymerized from one or more branch-point amino acid units and one or more copolymerized amino acid units;
the branch point amino acid unit is glutamic acid, lysine, ornithine, arginine, histidine, asparagine, glutamine, serine, tryptophan, aspartic acid, threonine, tyrosine or cysteine;
the copolymerized amino acid unit is glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline or methionine.
Preferably, the two or more amino acid units comprise at least one basic amino acid unit.
More preferably, the two or more amino acid units include at least one or more of lysine, arginine, ornithine and histidine.
In certain embodiments of the invention, the branched polyamino acid is copolymerized from arginine and alanine, or from ornithine and leucine, or from lysine and alanine, or from histidine and phenylalanine, or from lysine and arginine.
The method for preparing the branched polyamino acid is not particularly limited in the present invention, and the branched polyamino acid can be prepared according to a method well known to those skilled in the art, and preferably according to the following method:
mixing amino acids, and reacting at 25-250 ℃ for 1 min-96 h in an inert gas atmosphere to obtain the branched polyamino acid.
The inert gas is preferably nitrogen.
The reaction temperature is preferably 150-200 ℃, and the reaction time is preferably 30 min-24 h, and more preferably 2 h-12 h.
In certain embodiments of the invention, the terminal amino group in the branched polyamino acid may be modified to the following group:
wherein X, Y, Z, Q is independently selected from hydrogen, C1-C22 alkyl and its derivatives, C6-C30 aryl and its derivatives, C3-C18 cycloalkyl and its derivatives, C2-C18 alkene, alkyne and its derivatives, C1-C18 alkoxy and its derivatives, carboxylic acid and its derivatives, amine and its derivatives, nitrogen heterocycle and its derivatives, oxygen heterocycle and its derivatives or sulfur heterocycle and its derivatives.
The derivative is preferably C1-C5 alkyl substituent, C1-C5 alkoxy substituent, halogen, hydroxyl, sulfydryl, nitro, cyano, C5-C8 aryl, C5-C8 heteroaryl, C3-C5 cycloalkyl, carboxyl, amino, amido substituent, or any one or more C atoms are replaced by O or S.
More preferably, X, Y, Z, Q is independently selected from hydrogen, C1-C4 alkyl or amino.
The method of modification in the present invention is not particularly limited, and a method of amino acid modification known to those skilled in the art may be used.
The terminal amino group refers to a branched polyamino acidOf (2) is-NH2A group.
According to the invention, the bacteriostatic agent can further comprise an auxiliary agent, and the content of the auxiliary agent is preferably 0-99 wt%.
The kind of the adjuvant is not particularly limited in the present invention, and may be one suitable for bacteriostatic agents well known to those skilled in the art.
The bacteriostatic adjuvant preferably comprises: [i] inorganic bacteriostatic agents such as metals, metal ions, metal salts and oxides thereof; [ ii ] organic bacteriostatic agents such as organic metals, organic halides, guanidines, organic nitro compounds, organic phosphorus and organic arsenic compounds, furan and derivatives thereof, pyrrole, imidazole, acylaniline, thiazole and derivatives thereof, quaternary ammonium salts and the like; (iii) one or more of natural bacteriostatic agents such as natural bacteriostatic peptides, macromolecular saccharides and the like; [ iv ] non-toxic additives or carriers such as glycerin, PEG, high molecular saccharides, polypeptides, plastics, ceramics, glass, apatite, resins, fibers, rubbers, and the like.
More preferably, the bacteriostatic auxiliary agent is metal Ti, Ag+，Cu2+，Fe3+,Zn2+One or more of quaternary ammonium salt, halamine, polybiguanides, halogenated phenol, chitosan, protamine, natural antibacterial peptide and the like.
In certain embodiments of the invention, the adjuvant is polyhexamethylene biguanide.
The formulation of the bacteriostatic agent is not particularly limited in the invention, and the bacteriostatic agent can be solid, solution, suspension, emulsion, hydrogel, oleogel, aerosol, grafted on the surface of the solid, and mixed with polymer in one or more states for use.
The preparation method of the bacteriostatic agent is not particularly limited, and the branched polyamino acid and the auxiliary agent are mixed.
The mixing process may or may not use a solvent.
The solvent may be water or an organic solvent.
The organic solvent is preferably one or more of methanol, ethanol, ethyl acetate, n-heptane, dimethylformamide, dimethylacetamide, tetrahydrofuran, chloroform, dichloromethane, carbon tetrachloride, acetonitrile, petroleum ether, n-hexane, cyclohexane, dioxane, dimethyl sulfoxide, xylene, toluene, benzene, chlorobenzene, bromobenzene, acetone and ionic liquid.
The bacteriostatic agent provided by the invention has the advantages of simple preparation process, low equipment requirement, easiness in operation, easiness in obtaining materials, low cost, industrial application prospect and broad-spectrum bacteriostatic property.
The invention also provides application of the bacteriostatic agent in inhibiting one or more of gram-negative bacteria, gram-positive bacteria and fungi.
The bacteriostatic agent can be applied to the fields of food, cosmetics, hygienic products, medical products and the like.
Such as food preservative, cosmetic additive, mouthwash, disinfectant, multifunctional care solution, preservative in eye drops, swimming pool disinfectant, and can also be used for toothpaste, facial cleanser, hand sanitizer, disinfectant soap, disinfectant preservative for fruit and vegetable storage, etc.
Compared with the prior art, the invention provides a branched polyamino acid bacteriostatic agent, which consists of branched polyamino acid and an auxiliary agent; the branched polyamino acid is obtained by copolymerizing two or more than two amino acid units; the amino acid unit is arginine, alanine, ornithine, leucine, lysine, histidine or phenylalanine. The raw materials used by the invention are various amino acids, are all natural biological materials, have no toxicity and no side effect, are a novel environment-friendly bacteriostatic agent, and are easy to accept by users. The branched structure of the polyamino acid enables the substance to have a plurality of active functional groups, can be further modified, has good biocompatibility, can tear a bacterial film to cause death, and cannot generate drug resistance after long-term use.
Drawings
FIG. 1 shows the nuclear magnetic hydrogen spectrum of a branched polyamino acid prepared in example 3 of the present invention.
Detailed Description
In order to further illustrate the present invention, the following examples are provided to describe the branched polyamino acid bacteriostatic agent, its preparation method and application in detail.
In the present invention, the reaction materials used in the following examples are all commercially available products.
Example 1
Adding 80 g of arginine and 20g of alanine into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is longer than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 180 ℃ for reaction for 4 hours, stopping heating, then cooling the reaction system to room temperature, and dissolving and precipitating a polymer into ether by using methanol to obtain 78.7 g of hyperbranched polyamino acid.
Example 2
Adding 50 g of ornithine, 50 g of leucine and 10mg of scandium trifluoromethanesulfonate into a 500mL round-bottom flask, connecting a water distribution device, changing nitrogen for three times, wherein each time is longer than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 180 ℃ for reaction for 4 hours, stopping heating, and dissolving and precipitating a polymer into ether by using methanol to obtain 81.5 g of hyperbranched polyamino acid.
Example 3
91.32 g of lysine hydrochloride, 28.05 g of KOH and 20g of alanine were added to a 500mL round-bottomed flask, a water-dividing apparatus was connected, nitrogen was purged three times for more than 10 minutes each, finally, a nitrogen atmosphere was maintained, the reaction was heated with stirring at 180 ℃ for 4 hours, heating was stopped, then the reaction system was cooled to room temperature, and the polymer was dissolved in methanol and precipitated into ether to give 75.2 g of a branched polyamino acid.
The nuclear magnetic hydrogen spectrum of the synthesized branched polyamino acid is shown in figure 1.
Example 4
Adding 90 g of histidine, 10 g of phenylalanine and 10mg of ferric trichloride into a 500mL round-bottom flask, connecting a water diversion device, pumping nitrogen for three times, wherein each time is more than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 180 ℃ for reaction for 4 hours, stopping heating, cooling the reaction system to room temperature, and dissolving and precipitating a polymer into diethyl ether by using methanol to obtain 79.5 g of hyperbranched polyamino acid.
Example 5
Adding 80 g of ornithine and 20g of 6-aminocaproic acid into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is more than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 180 ℃ for reaction for 4 hours, stopping heating, cooling the reaction system to room temperature, dissolving the polymer with methanol, and precipitating the polymer into ether to obtain 82.3 g of hyperbranched polyamino acid.
Example 6
Adding 91.32 g of lysine hydrochloride, 20g of NaOH and 20g of alanine into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is more than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 180 ℃ for reaction for 36 hours, stopping heating, cooling the reaction system to room temperature, dissolving the polymer by using methanol, and precipitating the polymer into ether to obtain 74.8 g of hyperbranched polyamino acid.
Example 7
Adding 91.32 g of lysine hydrochloride, 20g of NaOH and 20g of alanine into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is more than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 100 ℃ for reaction for 96 hours, stopping heating, cooling the reaction system to room temperature, and dissolving and precipitating a polymer into ether by using methanol to obtain 72.8 g of hyperbranched polyamino acid.
Example 8
Adding 91.32 g of lysine hydrochloride, 20g of NaOH and 20g of alanine into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is more than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 250 ℃ for reaction for 1 hour, stopping heating, cooling the reaction system to room temperature, dissolving the polymer by using methanol, and precipitating the polymer into ether to obtain 73.1 g of hyperbranched polyamino acid.
Example 9
Adding 50 g of lysine and 50 g of arginine into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is longer than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 180 ℃ for reaction for 4 hours, stopping heating, then cooling the reaction system to room temperature, dissolving the polymer with methanol, and precipitating the polymer into ether to obtain 80.1 g of branched polyamino acid.
Example 10
2g of the hyperbranched polyamino acid prepared in example 2 was dissolved in 5mL of methanol, 4g of 1H-pyrazole-1-carboxamidine hydrochloride and 4mL of triethylamine were added, the reaction was carried out at 65 ℃ for 12 hours, then the heating was stopped, the reaction solution was cooled to room temperature, and the reaction solution was precipitated in ether to obtain 2.1g of a guanidino-modified hyperbranched polyamino acid.
Example 11
2g of the hyperbranched polyamino acid prepared in example 8 was dissolved in 5mL of methanol, 4g of 1H-pyrazole-1-carboxamidine hydrochloride and 4mL of triethylamine were added, the reaction was carried out at 65 ℃ for 12 hours, then the heating was stopped, the reaction solution was cooled to room temperature, and the reaction solution was precipitated in ether to obtain 2.2g of a guanidino-modified hyperbranched polyamino acid.
Example 12
Adding 20g of phenylalanine, 10 g of alanine, 70 g of lysine hydrochloride and 20g of KOH into a 500mL round-bottom flask, connecting a water distribution device, pumping nitrogen for three times, wherein each time is more than 10 minutes, finally keeping the nitrogen atmosphere, stirring and heating at 100 ℃ for reaction for 96 hours, stopping heating, cooling the reaction system to room temperature, and dissolving and precipitating a polymer into ether by using methanol to obtain 68.5 g of hyperbranched polyamino acid.
Example 13
Heating and dissolving 2g of the hyperbranched polyamino acid obtained in the example 3 in 20mL of DMF, adding 5g of bromobutane, stirring and reacting at 80 ℃ for 24 hours, stopping heating, cooling to room temperature, and settling in ethyl acetate to obtain 2.4g of the quaternary ammonium salt modified hyperbranched polyamino acid.
Example 14
2g of the hyperbranched polyamino acid prepared in example 6 and 2g of polyhexamethylene biguanide were dissolved in 5mL of water, uniformly dispersed with stirring, and then lyophilized to obtain 4g of a mixture of the hyperbranched polyamino acid and polyhexamethylene biguanide.
Example 15
2g of the hyperbranched polyamino acid prepared in example 2 and 2g of polyhexamethylene biguanide were dissolved in 5mL of water, uniformly dispersed with stirring, and then lyophilized to obtain 4g of a mixture of the hyperbranched polyamino acid and polyhexamethylene biguanide.
Example 16
36mg of the hyperbranched polyamino acid prepared in examples 1-15 are respectively dissolved by 3mL of sterile PBS to obtain 12mg/mL mother liquor, and the antibacterial activity of the hyperbranched polyamino acid-based antibacterial agent is tested according to the following method, and the experimental results are shown in tables 1 and 2.
The various strains used in the following examples were purchased from the china biologicals institute.
The antibacterial activity of the hyperbranched polyamino acid-based antibacterial agent is detected by a 96-well plate method, epsilon-polylysine synthesized by a fermentation method is used as a reference to evaluate the antibacterial capability of the obtained hyperbranched polyamino acid-based antibacterial agent, and the Minimum Inhibitory Concentration (MIC) is defined as the lowest polymer concentration which inhibits 90% of bacterial growth compared with a control group.
Selecting a small amount of strains from an agar slant culture medium by using an inoculating loop, culturing at 37 ℃ overnight to recover the strains and achieve exponential growth, diluting the bacteria liquid to make the concentration of the bacteria liquid be 106CFU/mL, adding 175 mu L of bacteria liquid and 25 mu L of polymer solution with different concentrations into each hole, culturing a 96-hole plate at 37 ℃ for 20H, and detecting the OD600 value by using a microplate reader.
TABLE 1
TABLE 2
Example 17
36mg of the hyperbranched polyamino acids prepared in examples 1 to 15 were respectively dissolved in 3mL of sterile PBS to obtain a mother solution of 12mg/mL, and the antibody extravascular hemolytic activity of the hyperbranched polyamino acid-based antibacterial agent was tested according to the following method, and the experimental results are shown in tables 3 and 4.
And (3) detecting the in vitro hemolytic activity of the hyperbranched polyamino acid-based antibacterial agent by adopting a 96-well plate method, and evaluating the in vitro hemolytic activity of the obtained hyperbranched polyamino acid-based antibacterial agent by taking epsilon-polylysine synthesized by a fermentation method as a reference.
Preparing 2% (v/v) erythrocyte suspension, taking 2mL of fresh healthy human blood, diluting with 10mL of PBS buffer solution without endotoxin, putting the diluted blood into a triangular flask containing glass beads, shaking for 10 minutes, or stirring the blood with a glass rod, removing fibrous protein to enable the blood to become defibrinated, centrifuging for 10-15 minutes at 1000-1500 r/min at 20 ℃, removing supernatant, and washing the precipitated erythrocytes for 4 times by using the PBS buffer solution according to the method until the supernatant does not show red. The obtained red blood cells are prepared into 2 percent suspension by using normal saline for subsequent tests.
The polymer was diluted with PBS buffer solution to prepare solutions of different concentrations, added to a 96-well plate, PBS buffer solution alone was used as a negative control, 0.2% Triton-X-100 was dissolved in water as a positive control for in vitro hemolytic activity detection, and washed erythrocytes (2% v/v, 50. mu.L) were added to the 96-well plate, mixed well and cultured. The absorbance at 540nm was measured with a microplate reader.
TABLE 3
TABLE 4
Example 18
This example was used to test the acute toxicity of hyperbranched polyamino acid based antibacterial agents in animals and the control was epsilon-polylysine synthesized by fermentation to evaluate the resulting hyperbranched polyamino acid based antibacterial agents for acute toxicity in animals.
100 mice were treated with 31. + -.3 g of each of the male and female halves, and the hyperbranched polyamino acid-based antibacterial agents prepared in examples 1 to 15 were administered to the mice at a dose of 1mg/mL once a day for 15 consecutive days to observe the toxic reaction of the mice. The experimental result shows that after the continuous intramuscular injection for 15 days, except the activity of individual mice is reduced, the rest mice have no obvious abnormal reaction, and all mice survive, which proves that the obtained hyperbranched polyamino acid based antibacterial agent has smaller in vivo toxicity.
As can be seen from the examples and comparative examples, the hyperbranched polyamino acid based antibacterial agent prepared by the invention has excellent antibacterial performance, no toxicity and no side effect.
The above description of the embodiments is only intended to facilitate the understanding of the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.
Claims (9)
1. A branched polyamino acid bacteriostatic agent is characterized by comprising branched polyamino acid;
the branched polyamino acid is obtained by copolymerizing two or more than two amino acid units;
the amino acid unit has a general structural formula shown in formula I or a salt thereof:
wherein,
a. b, c, d, e and f are independent integers of 0-6, and a + b + c + d + e + f is more than or equal to 1 and less than or equal to 20;
the T is1、T2、T3、T4、T5And T6Independently selected from any of the following structures:
and T of at least one amino acid1、T2、T3、T4、T5、T6At least one of which is
2. The bacteriostatic agent according to claim 1, wherein a + b + c + d + e + f is less than or equal to 10.
3. The bacteriostatic agent according to claim 1, wherein the branched polyamino acid is obtained by copolymerizing two or more branch-point amino acid units; or is copolymerized from one or more branch-point amino acid units and one or more copolymerized amino acid units;
the branch point amino acid unit is glutamic acid, lysine, ornithine, arginine, histidine, asparagine, glutamine, serine, tryptophan, aspartic acid, threonine, tyrosine or cysteine;
the copolymerized amino acid unit is glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline or methionine.
4. The bacteriostatic agent according to claim 1, wherein the two or more amino acid units comprise at least one basic amino acid unit.
5. The bacteriostatic agent according to claim 1 or 4, wherein the two or more amino acid units comprise at least one or more of lysine, ornithine, arginine and histidine.
6. The bacteriostatic agent according to claim 1, wherein the terminal amino groups in the branched polyamino acid are modified to the following groups:
wherein X, Y, Z, Q is independently selected from hydrogen, C1-C22 alkyl and its derivatives, C6-C30 aryl and its derivatives, C3-C18 cycloalkyl and its derivatives, C2-C18 alkene, alkyne and its derivatives, C1-C18 alkoxy and its derivatives, carboxylic acid and its derivatives, amine and its derivatives, nitrogen heterocycle and its derivatives, oxygen heterocycle and its derivatives or sulfur heterocycle and its derivatives.
7. The bacteriostatic agent according to claim 1, further comprising an adjuvant.
8. The bacteriostatic agent according to claim 1, wherein the bacteriostatic agent is a solid, a solution, a suspension, an emulsion, a hydrogel, an oleogel, an aerosol, grafted to a solid surface, and mixed with a polymer in one or more of the states.
9. Use of a bacteriostatic agent according to any one of claims 1 to 8 for inhibiting one or more of gram negative bacteria, gram positive bacteria and fungi.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111043610.6A CN113621135A (en) | 2018-01-31 | 2018-01-31 | Branched polyamino acid bacteriostatic agent and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810096221.1A CN108276572A (en) | 2018-01-31 | 2018-01-31 | A kind of branched polyaminoacid bacteriostatic agent and application |
| CN202111043610.6A CN113621135A (en) | 2018-01-31 | 2018-01-31 | Branched polyamino acid bacteriostatic agent and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810096221.1A Division CN108276572A (en) | 2018-01-31 | 2018-01-31 | A kind of branched polyaminoacid bacteriostatic agent and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113621135A true CN113621135A (en) | 2021-11-09 |
Family
ID=62807099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810096221.1A Pending CN108276572A (en) | 2018-01-31 | 2018-01-31 | A kind of branched polyaminoacid bacteriostatic agent and application |
| CN202111043610.6A Pending CN113621135A (en) | 2018-01-31 | 2018-01-31 | Branched polyamino acid bacteriostatic agent and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810096221.1A Pending CN108276572A (en) | 2018-01-31 | 2018-01-31 | A kind of branched polyaminoacid bacteriostatic agent and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108276572A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561810A (en) * | 2022-03-07 | 2022-05-31 | 中国科学院长春应用化学研究所 | Antibacterial anti-mite fabric and preparation method thereof |
| CN114983872A (en) * | 2022-05-30 | 2022-09-02 | 浙江大学 | Swallowable bead-blasting mouth wash with excellent blood compatibility and preparation method thereof |
| WO2023231050A1 (en) * | 2022-05-30 | 2023-12-07 | 浙江大学 | Tough antibacterial hydrogel dressing and preparation method therefor |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019149121A1 (en) * | 2018-01-31 | 2019-08-08 | 中国科学院长春应用化学研究所 | Branched polyamino acid bacteriostatic agent and application thereof |
| WO2021004845A1 (en) * | 2019-07-08 | 2021-01-14 | Basf Se | Lysine-branched copolymer |
| CN115197432B (en) * | 2021-04-08 | 2024-03-26 | 中国科学院长春应用化学研究所 | Antibacterial/antiviral polymer material and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080292675A1 (en) * | 2007-03-09 | 2008-11-27 | Erich Edermatt | Antimicrobial medicotechnical product, process for its production and use |
| US20080292671A1 (en) * | 2005-09-09 | 2008-11-27 | Aesculap Ag & Co. Kg | Antimicrobial Medicotechnical Product, Process for its Preparation and Use |
| CN101575412A (en) * | 2009-06-12 | 2009-11-11 | 武汉大学 | Hyperbranched polyamino acid, preparation method and application thereof |
| CN106832260A (en) * | 2016-12-22 | 2017-06-13 | 苏州度博迈医疗科技有限公司 | A kind of degradable antibacterial polyaminoacid and preparation method thereof |
| CN106832265A (en) * | 2017-03-15 | 2017-06-13 | 长春鑫螯科技有限公司 | A kind of method of Crosslinked Polyaminated acid type metal absorbent, preparation method and adsorbing metal |
| CN107033833A (en) * | 2017-03-15 | 2017-08-11 | 中国科学院长春应用化学研究所 | A kind of polyaminoacid composition and its preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2551326A1 (en) * | 2011-07-28 | 2013-01-30 | Basf Se | Use of polylysine as shale inhibitor |
-
2018
- 2018-01-31 CN CN201810096221.1A patent/CN108276572A/en active Pending
- 2018-01-31 CN CN202111043610.6A patent/CN113621135A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080292671A1 (en) * | 2005-09-09 | 2008-11-27 | Aesculap Ag & Co. Kg | Antimicrobial Medicotechnical Product, Process for its Preparation and Use |
| US20080292675A1 (en) * | 2007-03-09 | 2008-11-27 | Erich Edermatt | Antimicrobial medicotechnical product, process for its production and use |
| CN101575412A (en) * | 2009-06-12 | 2009-11-11 | 武汉大学 | Hyperbranched polyamino acid, preparation method and application thereof |
| CN106832260A (en) * | 2016-12-22 | 2017-06-13 | 苏州度博迈医疗科技有限公司 | A kind of degradable antibacterial polyaminoacid and preparation method thereof |
| CN106832265A (en) * | 2017-03-15 | 2017-06-13 | 长春鑫螯科技有限公司 | A kind of method of Crosslinked Polyaminated acid type metal absorbent, preparation method and adsorbing metal |
| CN107033833A (en) * | 2017-03-15 | 2017-08-11 | 中国科学院长春应用化学研究所 | A kind of polyaminoacid composition and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 徐孝华主编: "《普通微生物学》", 31 May 1992, 北京农业大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561810A (en) * | 2022-03-07 | 2022-05-31 | 中国科学院长春应用化学研究所 | Antibacterial anti-mite fabric and preparation method thereof |
| CN114983872A (en) * | 2022-05-30 | 2022-09-02 | 浙江大学 | Swallowable bead-blasting mouth wash with excellent blood compatibility and preparation method thereof |
| CN114983872B (en) * | 2022-05-30 | 2023-11-28 | 浙江大学 | Swallowing bead-bursting mouthwash with excellent blood compatibility and preparation method thereof |
| WO2023231050A1 (en) * | 2022-05-30 | 2023-12-07 | 浙江大学 | Tough antibacterial hydrogel dressing and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108276572A (en) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113717378A (en) | Branched polyamino acid bacteriostatic agent and application thereof | |
| CN113621135A (en) | Branched polyamino acid bacteriostatic agent and application thereof | |
| KR102541633B1 (en) | Branched polyamino acid antimicrobial agents and uses thereof | |
| CN108184852A (en) | A kind of polyaminoacid bacteriostatic agent and application | |
| Bai et al. | Enzymatic regulation of self-assembling peptide A9K2 nanostructures and hydrogelation with highly selective antibacterial activities | |
| Ghosh et al. | Small molecular antibacterial peptoid mimics: the simpler the better! | |
| Kaya et al. | New chitin, chitosan, and O-carboxymethyl chitosan sources from resting eggs of Daphnia longispina (Crustacea); with physicochemical characterization, and antimicrobial and antioxidant activities | |
| Thaya et al. | Synthesis of chitosan-alginate microspheres with high antimicrobial and antibiofilm activity against multi-drug resistant microbial pathogens | |
| Cao et al. | The impact of structure on elasticity, switchability, stability and functionality of an all-in-one carboxybetaine elastomer | |
| CN109988317B (en) | Amino acid modified lignin broad-spectrum antibacterial agent and preparation method and application thereof | |
| Peng et al. | Structure–activity study of antibacterial poly (ester urethane) s with uniform distribution of hydrophobic and cationic groups | |
| Mauro et al. | Branched high molecular weight glycopolypeptide with broad-spectrum antimicrobial activity for the treatment of biofilm related infections | |
| CN103435686B (en) | Anti-drug resistance bacteriological infection peptide C bf-14 and uses thereof | |
| Fei et al. | Identification of new nitric oxide-donating peptides with dual biofilm eradication and antibacterial activities for intervention of device-related infections | |
| CN104672348A (en) | Chitosan quaternary ammonium salt derivatives with good water solubility and antibacterial activity and preparation method of chitosan quaternary ammonium salt derivatives | |
| CN113121666B (en) | Antibacterial peptide Scybaumanncin 105-127 And applications thereof | |
| Li et al. | Membrane-active amino acid-coupled polyetheramine derivatives with high selectivity and broad-spectrum antibacterial activity | |
| CN101851270A (en) | Polymyxin derivative and preparation method thereof | |
| Singh et al. | Sustainable processing and synthesis of nontoxic and antibacterial magnetic nanocomposite from spider silk in neoteric solvents | |
| Li et al. | O‐Mannosylation Affords a Glycopeptide Hydrogel with Inherent Antibacterial Activities against E. coli via Multivalent Interactions between Lectins and Supramolecular Assemblies | |
| WO2020174340A1 (en) | Eutectic menthol-fatty acid combinations for wound healing | |
| CN112791191B (en) | Novel antibacterial peptide caprylic acid conjugate capable of efficiently resisting protease hydrolysis and multidrug-resistant bacteria and application thereof | |
| Hu et al. | Poly (amino acid-hydroxyethyl methacrylate) s with chiral lysine and/or leucine side moieties and their antibacterial abilities for biomedical applications | |
| CN110447646B (en) | Amino acid modified branched polyetheramine cationic bacteriostatic agent and preparation method thereof | |
| CN111109272B (en) | Bio-based antibacterial agent and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211109 |
|
| RJ01 | Rejection of invention patent application after publication |